Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
122
Recruiting, any sponsor type, condition "skin and skin structure infections"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting122
- Completed1,119
122 trials
Showing 1 to 25, recently updated first.
Sinomune Pharmaceutical Co., LtdIndustry
NCT07668999 · 64 participants (planned) · Start Mar 31, 2027 · Primary completion Mar 31, 2027
Drug: ZYG24004 1% topical film-forming formulation; ZYG24004 3% topical film-forming formulation and 1 more · For: Tinea Pedis
Sites: Beijing, China
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
University of Sao Paulo General HospitalAcademic, hospital or other
NCT07341386 · 62 participants (planned) · Start Jun 25, 2026 · Primary completion Dec 20, 2027
Drug: Acyclovir (ACV) · For: Autoimmune Rheumatic Diseases; Recurrent Herpes Simplex; Prevention
Sites: São Paulo, Brazil
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)Pivotal-lookingRecruiting
Spyre Therapeutics, Inc.Industry
NCT07766005 · 150 participants (planned) · Start Oct 6, 2026 · Primary completion Oct 2027
Drug: SPY072; Placebo and 1 more · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Rogers, Arkansas; Irvine, California · 34 sites in all
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06855498 · 600 participants (planned) · Start Feb 28, 2025 · Primary completion Feb 28, 2028
Drug: povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Montgomery, Alabama; Phoenix, Arizona · 305 sites in all
- Topical Lactoferrin and Luliconazole, Alone or in Combination, for Tinea CorporisPivotal-lookingRecruiting
Kafrelsheikh UniversityAcademic, hospital or other
NCT07937020 · 100 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 2027
Drug: Lactoferrin 2% Cream; Luliconazole 1% Cream and 2 more · For: Tinea Corporis
Sites: Kafr ash Shaykh, Egypt
Incyte CorporationIncyte (INCY)
NCT07213973 · 40 participants (planned) · Start Feb 2, 2026 · Primary completion Mar 25, 2028
Drug: Povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Farmington, Connecticut · 28 sites in all
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07855276 · 30 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 29, 2027
Drug: LOU064; Placebo · For: Hidradenitis Suppurativa
Sites: San Diego, California; Mayfield Heights, Ohio
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07830329 · 300 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 24, 2028
Drug: Olatorepatide; Placebo · For: Hidradenitis Suppurativa
Sites: The Bronx, New York
- Finasteride and CutibacteriumRecruiting
University of WashingtonAcademic, hospital or other
NCT07731802 · 40 participants (planned) · Start Aug 31, 2026 · Primary completion Mar 31, 2027
Drug: Finasteride 5 mg; Placebo Control · For: Dihydrotestosterone; Periprosthetic Joint Infection (PJI); Cutibacterium Acnes
Sites: Seattle, Washington
- Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabPivotal-lookingRecruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestAcademic, hospital or other
NCT07387198 · 135 participants (planned) · Start May 29, 2026 · Primary completion Dec 31, 2029
Drug: Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles; Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. · For: Merkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Neoadjuvant Immunotherapy
Sites: Heidelberg, Germany; Mannheim, Germany; Tübingen, Germany · 12 sites in all
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07665437 · 710 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 15, 2031
Drug: Remibrutinib · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Fort Smith, Arkansas; North Little Rock, Arkansas · 61 sites in all
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
Oruka Therapeutics, Inc.Industry
NCT07783542 · 200 participants (planned) · Start Aug 21, 2026 · Primary completion Oct 2028
Drug: ORKA-002 · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 25 sites in all
Prof Dr Frank ButtgereitAcademic, hospital or other
NCT02719314 · 10,000 participants (planned) · Start Dec 2015 · Primary completion Jul 2029
Drug: Glucocorticoid treatment · For: Osteoporosis; Inflammatory Rheumatism
Sites: Berlin, Germany
Charles University, Czech RepublicAcademic, hospital or other
NCT05303805 · 50 participants (planned) · Start May 2, 2022 · Primary completion Oct 30, 2027
Drug: Sevoflurane · For: Leg Ulcer
Sites: Prague, Czechia
- COVID-19 Booster and IIV Schedule in Immunocompromised HostsPivotal-lookingRecruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT06599658 · 660 participants (planned) · Start Nov 20, 2024 · Primary completion Jan 31, 2028
Drug: Inactivated influenza vaccine (IIV) at baseline; COVID-19 Vaccines at a 3-month interval and 2 more · For: COVID 19; Influenza; Rheumatoid Arthritis (RA) and 5 more
Sites: Montreal, Canada · 3 sites in all
KTH BiopharmaIndustry
NCT07698886 · 70 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 15, 2027
Drug: Geniwa gel · For: HPV (Human Papillomavirus)-Associated; Genital Warts
Sites: Hanoi, Vietnam
- A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07225569 · 144 participants (planned) · Start Dec 29, 2025 · Primary completion Sep 22, 2027
Drug: SAR445399; Placebo · For: Hidradenitis Suppurativa
Sites: Scottsdale, Arizona; North Hollywood, California; Boynton Beach, Florida · 86 sites in all
Corvus Pharmaceuticals, Inc.Industry
NCT07828860 · 25 participants (planned) · Start Sep 17, 2026 · Primary completion Dec 2027
Drug: Soquelitinib · For: Hidradenitis Suppurativa (HS)
Sites: West Lafayette, Indiana; Bowling Green, Kentucky; Owensboro, Kentucky · 11 sites in all
- Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07170917 · 208 participants (planned) · Start Nov 6, 2025 · Primary completion Feb 9, 2027
Drug: Brivekimig; Placebo · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Scottsdale, Arizona; Northridge, California · 85 sites in all
National Cancer Institute (NCI)NIH
NCT05896839 · 16 participants (planned) · Start Jul 24, 2024 · Primary completion Aug 2, 2027
Drug: Ipilimumab; Nivolumab and 2 more · For: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8 and 10 more
Sites: La Jolla, California; Los Angeles, California; Washington D.C., District of Columbia · 26 sites in all
Harrison DermatologyAcademic, hospital or other
NCT07689188 · 10 participants (planned) · Start Sep 10, 2026 · Primary completion Mar 10, 2028
Drug: Roflumilast 0.3% topical foam · For: Hidradenitis Suppurativa (HS)
Sites: Missouri City, Texas
Incyte CorporationIncyte (INCY)
NCT07049575 · 24 participants (planned) · Start Nov 3, 2025 · Primary completion Dec 9, 2026
Drug: Ruxolitinib Cream · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Fountain Valley, California; Northridge, California · 21 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07115043 · 120 participants (planned) · Start Jul 29, 2025 · Primary completion Oct 2, 2029
Drug: AZD6750; rilvegostomig · For: Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma (Skin) and 6 more
Sites: Grand Rapids, Michigan; St Louis, Missouri; Pittsburgh, Pennsylvania · 13 sites in all
- Better Options for Lymphatic Filariasis TreatmentPivotal-lookingRecruiting
Medicines Development for Global HealthAcademic, hospital or other
NCT07159373 · 5,100 participants (planned) · Start Sep 28, 2026 · Primary completion Jun 2027
Drug: MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole; IDA - Ivermectin + DEC + albendazole · For: Lymphatic Filariasis; Scabies; Strongyloidiasis
Sites: Suva, Fiji
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.